MicroRNAs, cancer and cancer stem cells

被引：153
作者：
Zimmerman, Amy L. [1 ,3 ]
Wu, Shiyong [1 ,2 ]
机构：
[1] Ohio Univ, Dept Chem & Biochem, Athens, OH 45701 USA
[2] Ohio Univ, Edison Biotechnol Inst, Athens, OH 45701 USA
[3] Ohio Univ, Honors Tutorial Coll, Athens, OH 45701 USA
来源：
CANCER LETTERS | 2011年 / 300卷 / 01期
关键词：
MicroRNA; Stem cell; Cancer stem cell; RNAi technology; BCL-2 FAMILY PROTEINS; TUMOR-SUPPRESSOR P53; HUMAN LUNG CANCERS; PROSTATE-CANCER; PROSPECTIVE IDENTIFICATION; EXPRESSION PROFILES; MYELOID-LEUKEMIA; GENE-EXPRESSION; DOWN-REGULATION; NUCLEAR EXPORT;
D O I：
10.1016/j.canlet.2010.09.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MicroRNAs regulate self-renewal differentiation and division of cells via post-transcriptional gene silencing Aberrant microRNA levels specifically an overall downregulation are present in many cancers as compared to their normal tissue counterparts Therefore a potential therapeutic use of microRNAs is to correct these aberrant transcript levels involved in the signaling pathways of cancer This review focuses on the current knowledge of microRNAs and their involvement with cancer cells and cancer stem cells The methods currently being used to develop miRNA-based cancer therapeutics are examined and the limitations halting further progress are also discussed Published by Elsevier Ireland Ltd
引用
收藏
页码：10 / 19
页数：10
相关论文
共 142 条
  • [1] Sequence variants in SLITRK1 are associated with Tourette's syndrome
    Abelson, JF
    Kwan, KY
    O'Roak, BJ
    Baek, DY
    Stillman, AA
    Morgan, TM
    Mathews, CA
    Pauls, DA
    Rasin, MR
    Gunel, M
    Davis, NR
    Ercan-Sencicek, AG
    Guez, DH
    Spertus, JA
    Leckman, JF
    Dure, LS
    Kurlan, R
    Singer, HS
    Gilbert, DL
    Farhi, A
    Louvi, A
    Lifton, RP
    Sestan, N
    State, MW
    [J]. SCIENCE, 2005, 310 (5746) : 317 - 320
  • [2] The Bcl-2 apoptotic switch in cancer development and therapy
    Adams, J. M.
    Cory, S.
    [J]. ONCOGENE, 2007, 26 (09) : 1324 - 1337
  • [3] Cellular Delivery In Vivo of siRNA-Based Therapeutics
    Aigner, A.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (34) : 3603 - 3619
  • [4] Akao Y, 2006, ONCOL REP, V16, P845
  • [5] Prospective identification of tumorigenic breast cancer cells
    Al-Hajj, M
    Wicha, MS
    Benito-Hernandez, A
    Morrison, SJ
    Clarke, MF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) : 3983 - 3988
  • [6] Comparison of siRNA-induced off-target RNA and protein effects
    Aleman, Lourdes M.
    Doench, John
    Sharp, Phillip A.
    [J]. RNA, 2007, 13 (03) : 385 - 395
  • [7] MicroRNA functions in animal development and human disease
    Alvarez-Garcia, I
    Miska, EA
    [J]. DEVELOPMENT, 2005, 132 (21): : 4653 - 4662
  • [8] MRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes
    Behm-Ansmant, Isabelle
    Rehwinkel, Jan
    Doerks, Tobias
    Stark, Alexander
    Bork, Peer
    Izaurralde, Elisa
    [J]. GENES & DEVELOPMENT, 2006, 20 (14) : 1885 - 1898
  • [9] p53-mediated activation of miRNA34 candidate tumor-suppressor genes
    Bommer, Guido T.
    Gerin, Isabelle
    Feng, Ying
    Kaczorowski, Andrew J.
    Kuick, Rork
    Love, Robert E.
    Zhai, Yali
    Giordano, Thomas J.
    Qin, Zhaohui S.
    Moore, Bethany B.
    MacDougald, Ormond A.
    Cho, Kathleen R.
    Fearon, Eric R.
    [J]. CURRENT BIOLOGY, 2007, 17 (15) : 1298 - 1307
  • [10] The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities
    Bonci, Desiree
    Coppola, Valeria
    Musumeci, Maria
    Addario, Antonio
    Giuffrida, Raffaella
    Memeo, Lorenzo
    D'Urso, Leonardo
    Pagliuca, Alfredo
    Biffoni, Mauro
    Labbaye, Catherine
    Bartucci, Monica
    Muto, Giovanni
    Peschle, Cesare
    De Maria, Ruggero
    [J]. NATURE MEDICINE, 2008, 14 (11) : 1271 - 1277
12345678910